Ardea Biosciences to Present Preclinical Multi-Drug Combination Synergy Data on its Lead MEK Inhibitor, RDEA119, at the American Association for Cancer Research 100th Annual Meeting
Friday March 20, 8:30 am ET
SAN DIEGO--(BUSINESS WIRE)--Ardea Biosciences, Inc. (Nasdaq:RDEA - News) today announced that the Company will present data from preclinical studies of RDEA119, its lead mitogen-activated ERK kinase (MEK) inhibitor in development for the treatment of cancer, demonstrating synergy when administered in combination with multiple anti-cancer agents, at the American Association for Cancer Research 100th Annual Meeting 2009 in Denver, Colorado. Presentation Details are as follows:
Date/Time: Tuesday, April 21, 2009 from 8:00 AM – 12:00 PM Mountain Time
Session Title: Kinase Inhibitors 2
Poster Title: The Selective MEK Inhibitor RDEA119: Synergy with Multiple Classes of Anti-Cancer Agents
Abstract Number: 3700
Location: Hall B-F, Poster Section 35
About RDEA119
RDEA119, a non-ATP competitive, highly-selective MEK inhibitor for the potential treatment of cancer and inflammatory diseases is the Company's lead compound from its MEK inhibitor research and development program. RDEA119 has shown potential as a potent inhibitor of MEK, which is believed to play an important role in cancer cell proliferation, apoptosis and metastasis as well as inflammation. Preclinical and clinical results suggest that RDEA119 has favorable properties, including oral dosing, excellent selectivity and limited retention in the brain, which, in turn, may result in a reduced risk of central nervous system (CNS) side effects. RDEA119 is currently being evaluated in a Phase 1/2 study in combination with sorafenib (Nexavar®, Onyx Pharmaceuticals, Bayer HealthCare) and as a single agent in a Phase 1 study, both in advanced cancer patients.
surf's up......crikey
